Biopharmaceutical company developing and commercializing therapies for rare neurological diseases.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing therapies for individuals suffering from rare, debilitating neuromuscular and neurological conditions in the United States. At the forefront of its offerings is Firdapse, an oral formulation of amifampridine phosphate tablets specifically designed to treat Lambert-Eaton myasthenic syndrome (LEMS) in adult patients. Additionally, the company provides Ruzurgi, aimed at pediatric patients with LEMS, thereby catering to a broad spectrum of patient demographics.
Beyond its current treatments, Catalyst Pharmaceuticals is actively involved in expanding its therapeutic footprint. It is developing Firdapse for potential applications in MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. These initiatives underscore its commitment to addressing unmet medical needs across various rare diseases through innovative drug development and strategic partnerships.
The company operates under key licensing agreemments, including partnerships with BioMarin Pharmaceutical Inc. These collaborations facilitate the development and commercialization of specialized pharmaceutical products, enhancing Catalyst Pharmaceuticals' ability to bring novel treatments to market efficiently and effectively.
Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals, Inc. has evolved significantly since its inception. Formerly known as Catalyst Pharmaceutical Partners, Inc., the company rebranded to Catalyst Pharmaceuticals, Inc. in 2015, reflecting its ongoing dedication to pioneering advancements in the field of biopharmaceuticals.